Drugs Education Prevention and Policy
September 4, 2022
Jason B. Luoma, Brian Pilecki, Alan K. Davis et al.
13 citations
As evidence for psychedelic-assisted therapy accumulates, legalization becomes more likely. As a result, there is an increasing need for psychologists to become educated about psychedelics and their therapeutic effects as they will play an important role in disseminating this treatment. Therefore, understanding psychologists’ current attitudes toward psychedelics is integral in informing...
Psychoanalytic Dialogues
September 3, 2022
Jeffrey Guss
ABSTRACT As interest in psychedelics as treatments for psychological problems grows, it is important for psychoanalysts to learn about them. Our patients will come to us to discuss their psychedelic experiences; additionally, psychedelics deserve reconsideration as meaningful collaborators with our field, at both the theoretical and clinical levels. After a brief history of these agents, the...
Psychoanalytic Dialogues
September 3, 2022
Megan Rundel
ABSTRACT As the use of psychedelic agents become a part of mental health treatment, psychoanalysts have the challenge of theorizing how they affect the psyche and the relational field, as well as how they might become part of an analytic process. In this paper, I explore three aspects of psychedelic experience and some ways we might start to understand them in analytic terms. I discuss states...
Psychoanalytic Dialogues
September 3, 2022
Kevin M. Barrett
12 citations
After a two-decade moratorium on psychedelic research in the United States, new studies on psychedelic assisted psychotherapy have shown promising results in the treatment of psychiatric disorders and the betterment of well people. Little has been written in contemporary psychoanalytic journals about the possible use of psychoanalytic theory as an underpinning for this research. This paper...
Journal of Clinical Psychopharmacology
September 1, 2022
Collin M. Price, Allison A. Feduccia, Katrina Debonis
Abstract Background Among the renewed applications of psychedelic medicines in psychiatry, 3,4-methylenedioxymethamphetamine (MDMA)–assisted therapy for posttraumatic stress disorder (PTSD) has demonstrated the most promise in early small-scale studies. Recent exploratory analyses from prior clinical trials of MDMA-assisted therapy for PTSD have suggested that recent use of selective serotonin...
Psychiatric Annals
September 1, 2022
Michael Ljuslin, Kabir Nigam, Roxanne Sholevar et al.
4 citations
In addition to physical symptoms and treatment burden, people affected by serious illness experience psychological, social, and spiritual distress. Medical professionals who care for them, including psychiatrists and other mental health clinicians, attend to these multiple dimensions of suffering with the hope and promise of improving patients' quality of life. Yet anxiety, depression,...
Psychiatric Annals
September 1, 2022
Mitch Earleywine, Zachary Herrmann
5 citations
Initial promise and dire need have inspired the multiple research programs of the second psychedelic renaissance. Serotonergic psychedelics (psilocybin, lysergic acid diethylamide, and ayahuasca) have decreased end-of-life anxiety in cancer patients, treatment-resistant depression, alcohol dependence, social anxiety in autistic adults, and nicotine dependence when applied with supportive...
Neuroscience & Biobehavioral Reviews
September 1, 2022
Michiel van Elk, David Bryce Yaden
214 citations
This paper provides a critical review of several possible mechanisms at different levels of analysis underlying the effects and therapeutic potential of psychedelics. At the (1) biochemical level, psychedelics primarily affect the 5-HT2A receptor, increase neuroplasticity, offer a critical period for social reward learning, and have anti-inflammatory properties. At the (2) neural level,...
Cureus
August 25, 2022
Vedant N Hedau, Ashish P Anjankar
5 citations
Psychedelics are hallucinogenic drugs that alter the state of consciousness substantially. They bring about psychological, auditory, and visual changes. The psychedelics act on the brain, implying that they have a powerful psychological impact. One of the main factors contributing to disability worldwide is pain. The majority of people deal with pain on a daily basis. Living with chronic pain...
August 22, 2022
John M. Pederson, Kathryn Cowie, Averi Barrett et al.
BACKGROUND Psilocybin is a naturally occurring psychedelic that induces feelings of euphoria and spiritual awakening when administered in doses of approximately 20-30 mg/70 kg. In the last decade, there has been renewed interest in using psilocybin for major depressive disorder (MDD). OBJECTIVE This individual patient data meta-analysis will investigate the efficacy and safety of psilocybin for...